Harrow Health Inc. 11.875... (HROWM)
NASDAQ: HROWM
· Real-Time Price · USD
26.01
-0.01 (-0.05%)
At close: Jun 13, 2025, 3:52 PM
26.10
0.35%
After-hours: Jun 13, 2025, 04:00 PM EDT
Company Description
Harrow, Inc. engages in the development, production, and sale of innovative medications.
It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.
The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business.
The company was founded by Mark L.
Baum and Robert J.
Kammer in January 2006 and is headquartered in Nashville, TN.
Harrow Health Inc. 11.875% Senior Notes due 2027
| Country | United States |
| IPO Date | Dec 29, 2022 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Mark L. Baum |
Contact Details
Address: No Address available Nashville, United States | |
| Website | http://www.harrowinc.com |
Stock Details
| Ticker Symbol | HROWM |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | n/a |
| ISIN Number | US4158583074 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | 4 | Filing |
| Jun 09, 2025 | 8-K | Current Report |
| Jun 05, 2025 | 4 | Filing |
| May 14, 2025 | 4 | Filing |
| May 14, 2025 | 4/A | [Amend] Filing |
| May 14, 2025 | 4/A | [Amend] Filing |
| May 08, 2025 | 10-Q | Quarterly Report |
| May 08, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |